AAAAAA

   
Results: 1-18 |
Results: 18
Pathologic features of prostate cancer found at population-based screeningwith a four-year interval
Authors: Hoedemaeker, RF van der Kwast, TH Boer, R de Koning, HJ Roobol, M Vis, AN Schroder, FH
Citation: Rf. Hoedemaeker et al., Pathologic features of prostate cancer found at population-based screeningwith a four-year interval, J NAT CANC, 93(15), 2001, pp. 1153-1158
Nationwide breast cancer screening programme fully implemented in the Netherlands
Authors: Fracheboud, J de Koning, HJ Boer, R Groenewoud, JH Verbeek, ALM Broeders, MJM van Ineveld, BM Hendriks, JHCL de Bruyn, AE Holland, R van der Maas, PJ
Citation: J. Fracheboud et al., Nationwide breast cancer screening programme fully implemented in the Netherlands, BREAST, 10(1), 2001, pp. 6-11
Impact of systematic false-negative test results on the performance of faecal occult blood screening
Authors: Loeve, F Boer, R van Oortmarssen, GJ van Ballegooijen, M Habbema, JDF
Citation: F. Loeve et al., Impact of systematic false-negative test results on the performance of faecal occult blood screening, EUR J CANC, 37(7), 2001, pp. 912-917
In vitro and in vivo uroselectivity of B8805-033, an antagonist with high affinity at prostatic alpha(1A)- vs. alpha(1B)- and alpha(1D)-adrenoceptors
Authors: Eltze, M Boer, R Michel, MC Hein, P Testa, R Ulrich, WR Kolassa, N Sanders, KH
Citation: M. Eltze et al., In vitro and in vivo uroselectivity of B8805-033, an antagonist with high affinity at prostatic alpha(1A)- vs. alpha(1B)- and alpha(1D)-adrenoceptors, N-S ARCH PH, 363(6), 2001, pp. 649-662
Endoscopic colorectal cancer screening: a cost-saving analysis
Authors: Loeve, F Brown, ML Boer, R van Ballegooijen, M van Oortmarssen, GJ Habbema, JDF
Citation: F. Loeve et al., Endoscopic colorectal cancer screening: a cost-saving analysis, J NAT CANC, 92(7), 2000, pp. 557-563
Re: Improving the cost-effectiveness of colorectal cancer screening
Authors: Loeve, F Brown, ML Boer, R Habbema, JDF
Citation: F. Loeve et al., Re: Improving the cost-effectiveness of colorectal cancer screening, J NAT CANC, 92(20), 2000, pp. 1691-1692
Localization of the 1,4-dihydropyridine drug acceptor of P-glycoprotein toa cytoplasmic domain using a permanently charged derivative N-methyl dexniguldipine
Authors: Ferry, D Boer, R Callaghan, R Ulrich, WR
Citation: D. Ferry et al., Localization of the 1,4-dihydropyridine drug acceptor of P-glycoprotein toa cytoplasmic domain using a permanently charged derivative N-methyl dexniguldipine, INT J CL PH, 38(3), 2000, pp. 130-140
The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes
Authors: Boer, R Ulrich, WR Klein, T Mirau, B Haas, S Baur, I
Citation: R. Boer et al., The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes, MOLEC PHARM, 58(5), 2000, pp. 1026-1034
Investigation of design and bias issues in case-control studies of cancer screening using microsimulation
Authors: Connor, RJ Boer, R Prorok, PC Weed, DL
Citation: Rj. Connor et al., Investigation of design and bias issues in case-control studies of cancer screening using microsimulation, AM J EPIDEM, 151(10), 2000, pp. 991-998
Stage distribution at first and repeat examinations in breast cancer screening
Authors: Boer, R de Koning, H van Oortmarssen, G Warmerdam, P van der Maas, P
Citation: R. Boer et al., Stage distribution at first and repeat examinations in breast cancer screening, J MED SCREE, 6(3), 1999, pp. 132-138
Reduction in breast cancer mortality due to the introduction of mass screening in the Netherlands: comparison with the United Kingdom
Authors: van den Akker-van Marle, E de Koning, H Boer, R van der Maas, P
Citation: E. Van Den Akker-van Marle et al., Reduction in breast cancer mortality due to the introduction of mass screening in the Netherlands: comparison with the United Kingdom, J MED SCREE, 6(1), 1999, pp. 30-34
Withdrawing low risk women from cervical screening programmes - Conclusions cannot yet be drawn
Authors: van den Akker-van Marle, ME van Ballegooijen, M Boer, R van Oortmarssen, GJ Habbema, JDF
Citation: Me. Van Den Akker-van Marle et al., Withdrawing low risk women from cervical screening programmes - Conclusions cannot yet be drawn, BR MED J, 319(7201), 1999, pp. 58-58
NHS breast screening programme - Reply
Authors: Boer, R de Koning, H Threlfall, A Woodman, C Street, A Friedman, E
Citation: R. Boer et al., NHS breast screening programme - Reply, BR MED J, 318(7180), 1999, pp. 399-399
Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction
Authors: Boer, R Schroder, FH
Citation: R. Boer et Fh. Schroder, Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction, PROSTATE, 40(2), 1999, pp. 130-131
The resurrection engine of Michel de Certeau
Authors: Boer, R
Citation: R. Boer, The resurrection engine of Michel de Certeau, PARAGRAPH, 22(2), 1999, pp. 199-212
The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening
Authors: Loeve, F Boer, R van Oortmarssen, GJ van Ballegooijen, M Habbema, JDF
Citation: F. Loeve et al., The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening, COMPUT BIOM, 32(1), 1999, pp. 13-33
A longer breast carcinoma screening interval for women age older than 65 years?
Authors: Boer, R de Koning, HJ van der Maas, PJ
Citation: R. Boer et al., A longer breast carcinoma screening interval for women age older than 65 years?, CANCER, 86(8), 1999, pp. 1506-1510
Interval cancers in the Dutch breast cancer screening programme
Authors: Fracheboud, J de Koning, HJ Beemsterboer, PMM Boer, R Verbeek, ALM Hendriks, JHCL van Ineveld, BM Broeders, MJM de Bruyn, AE van der Maas, PJ
Citation: J. Fracheboud et al., Interval cancers in the Dutch breast cancer screening programme, BR J CANC, 81(5), 1999, pp. 912-917
Risultati: 1-18 |